Results 71 to 80 of about 7,683 (166)
Clinical Case Reports, Volume 14, Issue 7, July 2026.ABSTRACT Cutaneous Mycobacterium haemophilum infection may be missed due to its requirement for iron supplementation and low‐temperature incubation, making early consideration of NTM infection and use of molecular diagnostics essential, particularly in immunocompromised hosts where IRIS may mimic disease progression.
Angus Lane +7 more
wiley +1 more source
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
The Journal of Dermatology, Volume 53, Issue 7, Page 1026-1031, July 2026.ABSTRACT Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating ...
Luis Puig +14 more
wiley +1 more source
Frontiers in Microbiology, 2017 The objective of this study was to investigate the cross-resistance between rifampin (RIF) and rifabutin (RFB) among clinical Mycobacterium tuberculosis (MTB) isolates, and the correlations between specific rpoB mutations and the minimum inhibitory ...
Wei Jing +9 more
doaj +1 more source
Helicobacter, Volume 31, Issue 4, July/August 2026.ABSTRACT Background/Aims Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual‐priming oligonucleotide‐based polymerase chain reaction (DPO‐PCR)‐based tailored therapy has been adopted, and P‐CABs have become available.
Chang Seok Bang +14 more
wiley +1 more source
Сlinical and molecular aspects of helicobacter pylori resistance to antimicrobial drugs
Медицинский совет, 2013 The literature review tells about current views on the clinical and molecular aspects of antibiotic resistance of Helicobacter pylori (H. pylori). Today, the growing number of H.
Y. A. Kucheryaviy +2 more
doaj +1 more source
Tolerance and Pharmacokinetic Interactions of Rifabutin and Azithromycin [PDF]
, 2001 This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection.
Follansbee, S. +10 more
core +1 more source
MicrobiologyOpen, Volume 15, Issue 3, June 2026.A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Blanca Lorente‐Torres +13 more
wiley +1 more source
, 2017 Objectives: The safety of rifabutin replacing rifampicin among adults having rifampicin-related adverse reactions (ARs) during the treatment of tuberculosis remains unknown.
余忠仁;簡榮彥 +1 more
core +1 more source
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy [PDF]
, 2014 Background Pharmacokinetic interactions between rifampicin and protease inhibitors (PIs) complicate the management of HIV-associated tuberculosis. Rifabutin is an alternative rifamycin, for patients requiring PIs.
McIlleron, Helen +17 more
core +2 more sources
Crystal structure of rifabutin and BCL6-POZ domain.
, 2014 Electron density corresponding to rifabutin, following refinement, in the context of surrounding electron density demonstrating the proximity of (A) tyrosine58 from one monomer of the POZ dimer and (B) asparagine21 and arginine24 from the other monomer. (
John W. R. Schwabe (530387) +7 more
core +1 more source